NCT04996004 - A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

December 7, 2023

Study Completion Date

December 7, 2023

Conditions

Leiomyosarcoma

Interventions

DRUG

Ontorpacept (TTI-621)

Ontorpacept (TTI-621) will be administered by intravenous infusion.

DRUG

Doxorubicin

75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.

Trial Locations (23)

10022

Memorial Sloan Kettering Cancer Center 53rd street., New York

10065

Memorial Sloan Kettering Cancer Center - Main Campus, New York

Memorial Sloan Kettering Cancer Center 53rd street., New York

10604

MSK Westchester, Harrison

11101

Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City

11553

MSK Nassau, Uniondale

11725

MSK Commack., Commack

15232

UPMC Hillman Cancer Center, Pittsburgh

22031

Virginia Cancer Specialists, Fairfax

32224

Mayo Clinic Florida, Jacksonville

33612

Moffitt Cancer Center, Tampa

44106

University Hospitals Cleveland Medical Center, Cleveland

48109

University of Michigan, Ann Arbor

52242

University of Iowa Hospital and Clinics, Iowa City

53792

University of Wisconsin Clinical Science Center, Madison

90403

Sarcoma Oncology Research Center, Santa Monica

97239

Oregon Health & Science University (OHSU), Portland

Oregon Health and Science University - Center for Health and Healing 1 (CHH1), Portland

Oregon Health and Science University - Center for Health and Healing 2(CHH2), Portland

07920

MSK Basking Ridge., Basking Ridge

07601

Hackensack University Medical Center, Hackensack

07748

MSK Monmouth, Middletown

07645

MSK Bergen, Montvale